A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents

Conclusions The NeoVas BRS was noninferior to CoCr-EES for the primary endpoint of 1-year angiographic in-segment LL, and resulted in comparable 1-year clinical outcomes, including recurrent angina. (NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial; NCT02305485)

http://www.interventions.onlinejacc.org/cgi/content/short/11/3/260?rss=1

Source: Journal of the American College of Cardiology: Cardiovascular Interventions - February 5, 2018 Category: Cardiology Authors: Han, Y., Xu, B., Fu, G., Wang, X., Xu, K., Jin, C., Tao, L., Li, L., Hou, Y., Su, X., Fang, Q., Chen, L., Liu, H., Wang, B., Yuan, Z., Gao, C., Zhou, S., Sun, Z., Zhao, Y., Guan, C., Stone, G. W., on behalf of the NeoVas Randomized Controlled Trial Invest Tags: MOC Source Type: research